All News
FDA approves blockbuster Dupixent for chronic hives
And other biotech news updates brought to you by The Readout.
Read MoreTrump administration axes key STI lab amid dramatic rise in US syphilis cases
Chaotic cuts to CDC hit expert leadership and programs that surveil, test and research sexually transmitted diseasesThe Trump administration’s cuts to a sexually transmitted infection lab at the Cen
Read MoreMad Cow-Like Disease Deaths in U.S.; Measles in 27 States; Cannabis Potency Soars
(MedPage Today) -- Note that some links may require registration or subscription. MedPage Today is collecting stories of HHS staffers across all agencies affected by Trump administration cuts.
Read MoreSTAT+: Pharmalittle: We’re reading about a Novo challenge to Medicare talks, a scuttled FDA office, and more
Novo Nordisk argues Medicare should negotiate the price for six of its insulin products separately, though they contain the same active ingredient.
Read MoreThe NIH puts a further chokehold on universities, and Ireland braces for pharma tariffs
And other health news stories you need to start your week.
Read MoreSTAT+: Gilead says its therapy delayed growth of tumors in aggressive form of breast cancer
Gilead Sciences said a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women with a less common, but aggressive form of breast cancer.
Read MoreVgenomics & Meril Genomics collaborate to enhance precision medicine
Initiatives under this partnership include non-invasive prenatal testing, targeted next-generation sequencing for TB and whole exome sequencing for diagnosing rare diseases
Read MoreAbbVie launches Venetoclax in India
Through the launch of Venetoclax for the treatment of both Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL), AbbVie announced its entry into the Indian oncology market
Read MoreSTAT+: Immunovant replaces CEO, makes other changes as Roivant tightens control
The biotech company Immunovant announced changes to its management team, including the naming of a new chief executive, intended to give its majority owner greater control over its operations.
Read More